AstraZeneca PLC (NYSE:AZN) has recently made significant strides in the medical field, particularly in the treatment of various types of cancer. On March 16, 2026, the company announced that Imfinzi, in combination with FLOT chemotherapy, has received approval in the European Union for treating adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. This regimen involves treatment before and after surgery, followed by Imfinzi monotherapy. The approval was based on the results from the Phase III MATTERHORN trial, which were published in The New England Journal of Medicine.
In addition to this groundbreaking development, on March 10, 2026, Guggenheim raised its price target on AstraZeneca PLC (NYSE:AZN) to 16,000 GBp from 15,500 GBp and maintained a Buy rating. This adjustment came after updating its model following FY25 results and recent investor discussions.
Furthermore, on March 9, 2026, AstraZeneca PLC (NYSE:AZN) and Daiichi Sankyo announced that the supplemental biologics license application for Enhertu was accepted and granted priority review in the U.S. for patients with HER2-positive breast cancer with residual disease after prior treatment. These advancements highlight AstraZeneca’s commitment to developing innovative treatments for various types of cancer.
Moreover, Morgan Stanley recently raised its price target on AstraZeneca to $219 from $109 and maintained an Overweight rating. The firm cited updated risk/reward metrics and pointed to sector-leading earnings growth supported by a stronger pipeline outlook. This positive outlook suggests that AstraZeneca is well-positioned for continued success and growth in the coming years.
AstraZeneca PLC (NYSE:AZN) is a leading pharmaceutical company that develops and commercializes prescription medicines across multiple therapeutic areas, with a focus on oncology. The company’s recent successes in cancer treatment underscore its dedication to improving patient outcomes and advancing medical research.
While AstraZeneca shows promise as an investment opportunity, it’s important to consider other options that may offer greater upside potential and lower downside risk. For those interested in exploring alternative investment opportunities, particularly in the field of artificial intelligence, there are several undervalued AI stocks worth considering. To learn more about these opportunities, check out our free report on the best short-term AI stock.
In conclusion, AstraZeneca PLC (NYSE:AZN) continues to make significant strides in the medical field, particularly in the treatment of cancer. With recent approvals and positive outlook from analysts, the company is well-positioned for continued success and growth in the future. For investors looking to explore alternative investment opportunities, particularly in AI stocks, there are several promising options worth considering.
